Travere Therapeutics to Report First Quarter 2025 Financial Results
- SAN DIEGO--(BUSINESS WIRE)-- #1Q25Earnings--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Fo.
- 04/24/2025
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 31,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as.
- 04/11/2025
|
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
- SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere's late-breaking oral presentation at NKF details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS.
- 03/31/2025
|
Two S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market Struggles
- The stock market is attempting to rebound amid President Donald Trump's trade war. The post Two S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market Struggles appeared first on Investor's Business Daily.
- 03/29/2025
|
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
- sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Additionally, the FDA notified the Company that REMS monitoring for embryo-fetal toxicity is no longer necessary; the Company plans to submit an amendment to the REMS sNDA currently under review for modification of liver monitoring SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced the Company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking priority review for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The submission is supported by results from the Phase 3 DUPLEX Study and the Phase 2 DUET Study, two of the largest head-to-head interventional studies conducted to date in adult and pediatric patients with FSGS.
- 03/17/2025
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 77,200 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 41,200 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
- 03/12/2025
|
Travere Therapeutics to Participate at Upcoming Investor Conferences
- SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in March:
- 02/24/2025
|
Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript
- Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO William Rote - Senior Vice President of Research & Development Conference Call Participants Malcolm Kuno - JPMorgan Vamil Divan - Guggenheim Securities Joseph Schwartz - Leerink Partners Liisa Bayko - Evercore ISI Yigal Nochomovitz - Citigroup Prakhar Agrawal - Cantor Fitzgerald Fadi Ahman - Wells Fargo Gregory Harrison - Scotiabank Jason Zemansky - BofA Securities Alexander Thompson - Stifel Ed Arce - H.C. Wainwright Operator Good afternoon, and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call.
- 02/21/2025
|
Compared to Estimates, Travere (TVTX) Q4 Earnings: A Look at Key Metrics
- The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 02/20/2025
|
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates
- Travere Therapeutics (TVTX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $1.16 per share a year ago.
- 02/20/2025
|
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
- Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI ® (sparsentan) for FSGS
- 02/20/2025
|
Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
- Get a deeper insight into the potential performance of Travere (TVTX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 02/17/2025
|
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
- SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
- 02/13/2025
|
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/13/2025
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 115,100 shares of its common stock to ten new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 79,100 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
- 02/12/2025
|
Travere (TVTX) Moves 12.6% Higher: Will This Strength Last?
- Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 02/12/2025
|
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
- Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and leading cause of kidney failure sNDA submission to be based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has completed its Type C meeting with the U.S. Food and Drug Administration (FDA) and plans to submit a supplemental New Drug Application (sNDA) seeking traditional approval of FILSPARI for focal segmental glomerulosclerosis (FSGS).
- 02/11/2025
|
Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 42.6% in Travere (TVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 01/08/2025
|
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT.
- 01/06/2025
|
Travere Therapeutics: Cautiously Bullish Based On Improving Revenue
- Travere Therapeutics' sparsentan received full FDA approval for IgA nephropathy, showing long-term kidney function preservation and significant market growth, with $35mn in 3Q24 revenues. Despite setbacks in FSGS trials, ongoing studies and FDA involvement suggest potential future approval, bolstered by proteinuria reduction as a validated surrogate endpoint. Financially, TVTX faces high operating expenses and cash runway concerns but aims to extend runway to 2028 through restructuring and secondary offerings.
- 12/19/2024
|
Homocystinuria Therapeutics Market Research 2024: Insights About 3+ Companies and 3+ Pipeline Drugs Featuring Travere Therapeutics and Syntis Bio
- Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Homocystinuria - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Homocystinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
- 12/18/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/27/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/26/2024
|
Travere Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December:
- 11/25/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/22/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/18/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/16/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/14/2024
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 24,400 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
- 11/13/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/12/2024
|
3 Under-the-Radar Healthcare Companies
- The healthcare sector is vast and includes everything from massive legacy companies including UnitedHealth Group Inc. NYSE: UNH and McKesson Corp. NYSE: MCK to tiny upstart pharmaceuticals firms. Investors looking to explore this sector thus have a choice about whether to focus on established companies with steadier business operations but, perhaps, less of a possibility of future growth, or on smaller firms that offer a higher-risk, higher-reward prospect.
- 11/11/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/10/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/08/2024
|
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
- SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be $125.0 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on November 12, 2024, subject to customary closing conditions. In addition, Travere has granted the underwriters for the offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
- 11/07/2024
|
Travere Therapeutics Announces Proposed Public Offering of Common Stock
- SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, shares of its common stock. All of the shares are being offered by Travere. In addition, Travere intends to grant the underwriters for the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 11/07/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/06/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/04/2024
|
Travere Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in November:
- 11/04/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/02/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/31/2024
|
Travere Therapeutics, Inc. (TVTX) Q3 2024 Earnings Call Transcript
- Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Nivi Nehra - Vice President of Corporate Communications and Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO Bill Rote - Senior Vice President of Research & Development Conference Call Participants Anupam Rama - JPMorgan Greg Wiesner - TD Cowen Joe Thomas - Scotiabank Laura Chico - Wedbush Securities Sadia Rahman - Wells Fargo Operator Good morning, and welcome to the Travere Therapeutics' Third Quarter 2024 Financial Results Conference Call. Today's call is being recorded.
- 10/31/2024
|
Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
- The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 10/31/2024
|
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
- Travere Therapeutics (TVTX) came out with a quarterly loss of $0.70 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.17 per share a year ago.
- 10/31/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/27/2024
|
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
- Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS Study, PROTECT open-label extension, and real-world evidence presentations highlight initial safety and efficacy data of FILSPARI in combination treatment in IgAN Late-breaking presentation demonstrates sparsentan delivered rapid and sustained proteinuria reduction, and long-term kidney health benefits in a subset of patients with genetic, often treatment resistant, FSGS SAN DIEGO, Oct. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX), presented new data further demonstrating the clinical benefit of FILSPARI (sparsentan) in IgA nephropathy (IgAN) and reinforcing its potential in focal segmental glomerulosclerosis (FSGS) at the American Society of Nephrology (ASN) Kidney Week 2024. “The data presented at ASN provided additional evidence that FILSPARI is effective across all subgroups of IgAN patients studied to-date, and that it achieved significant levels of complete remission when used in newly diagnosed patients.
- 10/26/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/25/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/23/2024
|
Wall Street Analysts See a 26.27% Upside in Travere (TVTX): Can the Stock Really Move This High?
- The mean of analysts' price targets for Travere (TVTX) points to a 26.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 10/23/2024
|
Travere Therapeutics to Report Third Quarter 2024 Financial Results
- SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 8:30 a.m. ET.
- 10/21/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/19/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/17/2024
|
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
- SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). “FILSPARI targets damage directly in the kidney and offers patients a convenient, once daily, oral, non-immunosuppressive treatment that can provide superior results compared to maximally dosed irbesartan, supporting replacing their RASi,” said Eric Dube, Ph.D.
- 10/17/2024
|
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).
- 10/17/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/15/2024
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect
- NEW YORK CITY, NY / ACCESSWIRE / October 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/15/2024
|
Travere Therapeutics, Inc. (TVTX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
- NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
- 10/15/2024
|
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
- Data presentations highlight the results for FILSPARI ® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies Late-breaking presentation details outcomes of sparsentan's effect in a subgroup of high-risk patients with genetic focal segmental glomerulosclerosis SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including one late-breaking abstract at the upcoming American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, CA, October 23-27, 2024. Presentations will include new data from the SPARTAN Study highlighting efficacy and safety results of FILSPARI (sparsentan) in IgA nephropathy (IgAN) when used as a first-line treatment in newly diagnosed IgAN patients, an analysis from the PROTECT Study examining the clinical benefit of FILSPARI in IgAN regardless of participants' baseline proteinuria, as well as patient-reported outcomes from the PROTECT and DUPLEX Studies.
- 10/14/2024
|
Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation
- NEW YORK CITY, NY / ACCESSWIRE / October 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/14/2024
|
Investors who lost money on Travere Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - TVTX
- NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
- 10/14/2024
|
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
- NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. (“Travere” or “the Company”) (NASDAQ: TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/13/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/13/2024
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESSWIRE / October 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/13/2024
|
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)---- $TVTX #TravereTherapeutics--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. (“Travere” or “the Company”) (NASDAQ: TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX. Investigation Details On September 26, 2024, Travere issued a press release "announc[ing] a voluntary pause of e.
- 10/11/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/11/2024
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach Out
- NEW YORK CITY, NY / ACCESSWIRE / October 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/11/2024
|
Travere Therapeutics, Inc. (TVTX) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
- NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
- 10/11/2024
|
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
- NEW YORK , Oct. 10, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ: TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/10/2024
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Reach Out
- NEW YORK CITY, NY / ACCESSWIRE / October 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/10/2024
|
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
- As of Oct. 10, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
- 10/10/2024
|
Shareholders that Lost Money on Travere Therapeutics, Inc. (TVTX) Should Contact Levi & Korsinsky about Securities Fraud Investigation - TVTX
- NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
- 10/10/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/09/2024
|
Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease
- Travere Therapeutics stock popped Wednesday after a group of experts suggested an alternative means of measuring the success of FSGS drugs.
- 10/09/2024
|
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESSWIRE / October 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/09/2024
|
Travere Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Travere Therapeutics, Inc. (TVTX)
- NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
- 10/09/2024
|
Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation
- NEW YORK CITY, NY / ACCESSWIRE / October 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/08/2024
|
Levi & Korsinsky Announces an Investigation on Behalf of Travere Therapeutics, Inc. (TVTX) Shareholders Who May Have Been Affected by Fraud
- NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
- 10/08/2024
|
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
- NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. (“Travere” or “the Company”) (NASDAQ: TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/07/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 10/07/2024
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect
- NEW YORK CITY, NY / ACCESSWIRE / October 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/07/2024
|
Travere Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - TVTX
- NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
- 10/07/2024
|
Travere (TVTX) Surges 11.6%: Is This an Indication of Further Gains?
- Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 10/07/2024
|
Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation
- NEW YORK CITY, NY / ACCESSWIRE / October 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/06/2024
|
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
- NEW YORK , Oct. 2, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ: TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/02/2024
|
Investors Who Lost Money on Travere Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - TVTX
- NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
- 10/02/2024
|
Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation
- NEW YORK CITY, NY / ACCESSWIRE / October 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/02/2024
|
ATTENTION Travere Therapeutics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
- NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
- 10/01/2024
|
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
- NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. (“Travere” or “the Company”) (NASDAQ: TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/01/2024
|
Investors who lost money on Travere Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - TVTX
- NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
- 10/01/2024
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach Out
- NEW YORK CITY, NY / ACCESSWIRE / October 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
- 10/01/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, NY / ACCESSWIRE / September 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 09/30/2024
|
Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN
- Travere Therapeutics specializes in rare kidney and metabolic disease treatments with key drugs Filspari and Thiola. Filspari, a key asset for IgA Nephropathy, has received full FDA approval, and its market potential is significant if indications expand. Travere faces risks from supply constraints and paused Pegtibatinase trial, but these are seen as temporary headwinds rather than long-term issues.
- 09/30/2024
|
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
- SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
- 09/26/2024
|
Travere (TVTX) Soars 5.9%: Is Further Upside Left in the Stock?
- Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 09/17/2024
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 33,500 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
- 09/12/2024
|
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
- SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 9:45 a.m. ET.
- 09/10/2024
|
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
- The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.
- 09/09/2024
|
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
- Travere Therapeutics stock surged Friday after the biotech company snagged full FDA approval for its kidney disease treatment, Filspari.
- 09/06/2024
|
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
- JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Ligand is entitled to milestone payments and a 9% royalty on worldwide net sales of FILSPARI. FILSPARI was granted accelerated approval in.
- 09/06/2024
|
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
- FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that accrued over two years Conversion to full approval based on results from the PROTECT Study, where FILSPARI delivered superior long-term kidney function preservation compared to the active comparator irbesartan in the only Phase 3 head-to-head trial conducted in IgAN As an oral, non-immunosuppressive and dual acting, once-daily medicine with superior long-term results vs. irbesartan, FILSPARI has the potential to become foundational care in IgAN Company to host conference call September 5, 2024, at 6 p.m.
- 09/05/2024
|
Travere Therapeutics: Judgement Day Is Nigh For Sparsentan
- Travere Therapeutics' stock has been volatile due to Filspari's failed Phase 3 trials, but a full FDA approval is possible next week that could boost its share price. Despite setbacks, Filspari's unique dual-pathway mechanism and promising clinical data make FDA denial unlikely, supporting a bullish outlook. Travere's financial health is precarious, with significant losses and a potential need for additional funding, but a buyout could be a favorable outcome.
- 08/30/2024
|
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
- SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present two posters in classical homocystinuria (HCU) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) annual symposium in Porto, Portugal, September 3-6, 2024. At SSIEM, the Company will present the trial designs of the pivotal Phase 3 HARMONY Study and ENSEMBLE long-term extension study of pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of classical HCU.
- 08/22/2024
|
Travere Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August:
- 08/06/2024
|
Travere Therapeutics, Inc. (TVTX) Q2 2024 Earnings Call Transcript
- Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Nivi Nehra - Vice President of Corporate Communications and Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO Bill Rote - Senior Vice President of Research & Development Conference Call Participants Tyler Van Buren - TD Cowen Anupam Rama - JPMorgan Joseph Schwartz - Leerink Partners Carter Gould - Barclays Pavan Patel - Bank of America Maurice Raycroft - Jefferies Alex Thompson - Stifel Vamil Divan - Guggenheim Securities Thomas Yip - H.C. Wainwright Operator Good day, and welcome to the Travere Therapeutics' Second Quarter 2024 Financial Results and Corporate Update Conference Call.
- 08/03/2024
|
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
- While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 08/01/2024
|
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
- Travere Therapeutics (TVTX) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.13 per share a year ago.
- 08/01/2024
|
Travere Therapeutics Reports Second Quarter 2024 Financial Results
- Received 521 new patient start forms (PSFs) for FILSPARI ® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch
- 08/01/2024
|
Travere Therapeutics to Report Second Quarter 2024 Financial Results
- SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced it will report second quarter 2024 financial results on Thursday, August 1, 2024, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
- 07/25/2024
|
Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?
- Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 07/10/2024
|
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
- SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m.
- 07/08/2024
|
Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?
- Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 06/24/2024
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 10,500 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
- 06/11/2024
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 51,500 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 26,500 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
- 05/15/2024
|
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
- Presentations highlight data supporting FILSPARI ® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN
- 05/09/2024
|
Travere Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:
- 05/08/2024
|
Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript
- Start Time: 16:30 January 1, 0000 5:26 PM ET Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q1 2024 Earnings Conference Call May 06, 2024, 16:30 PM ET Company Participants Eric Dube - CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO Bill Rote - SVP of Research & Development Anne Crotteau - IR Conference Call Participants Anupam Rama - JPMorgan Tyler Van Buren - TD Cowan Joseph Schwartz - Leerink Partners Carter Gould - Barclays Jason Zemansky - Bank of America Maury Raycroft - Jefferies Yigal Nochomovitz - Citigroup Vamil Davin - Guggenheim Partners Alex Thompson - Stifel Laura Chico - Wedbush Securities Ed Arce - HC Wainwright & Co Allison Bratzla - Piper Sandler Operator Good day and welcome to the Travere Therapeutics First Quarter 2024 Financial Results and Corporate Update Conference Call. Today's call is being recorded.
- 05/06/2024
|
Here's What Key Metrics Tell Us About Travere (TVTX) Q1 Earnings
- While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 05/06/2024
|
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
- Travere Therapeutics (TVTX) came out with a quarterly loss of $1.76 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $1.27 per share a year ago.
- 05/06/2024
|
Travere Therapeutics Reports First Quarter 2024 Financial Results
- FDA grants Priority Review for sNDA to convert FILSPARI ® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024
- 05/06/2024
|
Travere Therapeutics to Report First Quarter 2024 Financial Results
- SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2024 financial results on Monday, May 6, 2024, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
- 04/29/2024
|
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- Travere and CSL Vifor announce EC approval of FILSPARI (sparsentan) for treatment of IgAN, 1st non-immunosuppressive treatment for IgAN approved in Europe
- 04/24/2024
|
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, April 24, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).
- 04/24/2024
|
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
- Travere to present abstracts at SIMD and GMDI highlighting research investigating pegtibatinase as the first potential disease-modifying therapy for HCU
- 04/04/2024
|
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
- SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina, on April 13-16, 2024, and the American Nephrology Nurses Association (ANNA) National Symposium in Orlando, Florida, on April 14-17, 2024. At WCN, the Company will present subgroup analyses of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) showing the treatment effect across participants with different levels of baseline proteinuria.
- 04/03/2024
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 51,600 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 26,600 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
- 03/13/2024
|
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
- Travere announces submission of an sNDA to the FDA for conversion of existing US accelerated approval of FILSPARI (sparsentan) in IgAN to full approval.
- 03/11/2024
|
Travere Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming investor conferences in March:
- 02/26/2024
|
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
- Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe
- 02/23/2024
|
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
- Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive CHMP opinion is based on pivotal phase-III PROTECT study results European Commission decision is expected in Q2 2024 ST. GALLEN, Switzerland , Feb. 23, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Medicines Agency's (EMA) CHMP has recommended approval of sparsentan for the treatment of adults with primary IgAN with a urine protein excretion >1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).
- 02/23/2024
|
Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript
- Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript
- 02/16/2024
|
Travere (TVTX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
- While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 02/15/2024
|
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Received 459 new patient start forms (PSFs) for FILSPARI ® (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023
- 02/15/2024
|
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
- SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 15, 2024, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
- 02/08/2024
|
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
- SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 11:30 a.m. ET.
- 02/01/2024
|
Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
- Travere (TVTX) is on track to file an sNDA to the FDA to convert the accelerated approval for lead drug, Filspari, to full approval for IgAN in first-quarter 2024.
- 01/24/2024
|
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 3:45 p.m. PT.
- 01/02/2024
|
Travere (TVTX) Up on Latest Portfolio Updates & Reorganization
- Travere (TVTX) to submit an sNDA to the FDA to convert the accelerated approval for Filspari to full approval for IgAN in first-quarter 2024. The company is implementing a strategic reorganization to cut costs.
- 12/06/2023
|
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
- SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 8:20 a.m. ET.
- 11/21/2023
|
Travere Therapeutics, Inc. (TVTX) Q3 2023 Earnings Call Transcript
- Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Naomi Eichenbaum - Vice President-Investor Relations Dr. Eric Dube - Chief Executive Officer Dr. Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer Dr. Bill Rote - Senior Vice President of Research & Development Conference Call Participants Anupam Rama - JP Morgan Maury Raycroft - Jefferies Greg Harrison - Bank of America Vamil Divan - Guggenheim Securities Liisa Bayko - Evercore.ISI Edwin Delfin - Barclays Laura Chico - Wedbush Securities Alex Thompson - Stifel Allison Bratzel - Piper Sandler Ed Arce - H.C. Wainwright & Company Operator Good day, and welcome to the Travere Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call.
- 11/07/2023
|
Travere Therapeutics to Report Third Quarter 2023 Financial Results
- SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
- 10/24/2023
|
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
- Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI ® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS
- 10/13/2023
|
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
- SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential effect of FILSPARI® (sparsentan) as a first-line therapy in patients with newly diagnosed IgA nephropathy (IgAN) in a late-breaking trial session at the 17th International Symposium on IgA Nephropathy (IIGANN2023) in Ryogoku, Tokyo, September 28-30, 2023.
- 09/26/2023
|
Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study
- Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.
- 09/22/2023
|
Travere Therapeutics: Tanking On Confirmatory Trial Failure For Kidney Therapy - Is There Hope?
- Travere Therapeutics stock tanked yesterday as the company reported its kidney disease drug FILSPARI had failed to meet its key endpoint in a confirmatory study. TVTX shares fell to ~$8 - down 40% for the day - analysts worried that FILSPARI could be withdrawn from the market, having been granted accelerated approval in Feb. Travere recently sold off its bile acid product portfolio to support its launch of FILSPARI - the division was the main revenue driver at the company.
- 09/22/2023
|
Why Shares of Travere Therapeutics Are Slumping Thursday
- Travere said that Filspari was promising in preserving kidney function. The therapy did not meet all of its endpoints in a phase 3 trial.
- 09/21/2023
|
Travere Therapeutics shares plunge as kidney-disease treatment has mixed results in trial
- Travere Therapeutics Inc. shares TVTX dropped 37% premarket on Thursday after the company released data from a late-stage study of Filspari in IgA nephropathy, a rare kidney disease. In a head-to-head study versus irbesartan, Filspari fell short of producing a statistically significant difference by one measure of kidney function, although patients on the treatment had some of the slowest annual rates of kidney function decline seen in IgA nephropathy clinical trials, Travere said in a release.
- 09/21/2023
|
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
- SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023, at 10:15 a.m. ET.
- 08/31/2023
|
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
- SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data from the Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Jerusalem, Israel, August 29 – September 1, 2023.
- 08/24/2023
|
Travere (TVTX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
- Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 08/03/2023
|
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
- Travere Therapeutics (TVTX) came out with a quarterly loss of $1.13 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.05 per share a year ago.
- 08/03/2023
|
Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc
- Deep Track Capital, LP (Trades, Portfolio), a prominent investment firm, recently made a significant move in the stock market by acquiring a new stake in Terns Pharmaceuticals Inc. This article will delve into the details of this transaction, provide an overview of both the guru and the traded company, and analyze the potential implications of this move for value investors.
- 07/28/2023
|
Biotech stock Travere Therapeutics is trading at a deep discount: JPMorgan
- Travere Therapeutics Inc (NASDAQ: TVTX) has been a disappointment for shareholders since early May but a JPMorgan analyst expects it to recover over the next 18 months. Travere Therapeutics shares have a 65% upside On Friday, Anupam Rama assumed coverage of the biotech stock with an “overweight” rating.
- 07/21/2023
|
Travere Therapeutics to Report Second Quarter 2023 Financial Results
- SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2023 financial results on Thursday, August 3, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
- 07/20/2023
|
Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say
- In light of a Novartis NVS, -0.94% deal to acquire Chinook Therapeutics Inc. KDNY, +58.09%, which is developing treatments for a rare kidney disease, two other companies focused on the same disease look even more attractive, analysts said Monday.
- 06/12/2023
|
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
- Navigating the turbulent waters in the biotech space is no mean feat. With the sector's inherent volatility due to testing clinical trials and regulatory hurdles, the road toward market approval can be incredibly challenging.
- 06/07/2023
|
Travere Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences:
- 06/01/2023
|
Travere: Turbulent Journey With FILSPARI, Downgrading To Sell
- FILSPARI's inability to significantly change FSGS disease trajectory (eGFR) in the Phase 3 DUPLEX study raises doubts about its IgAN trial and eventual approvability in FSGS. FILSPARI's sales, largely inventory-driven, may not predict actual market potential. We downgrade to sell rating as we are bearish on the PROTECT readout and also believe the upcoming sales data won't be a meaningful enough catalyst to change the trajectory.
- 05/29/2023
|
3 Biotech Stocks With Blockbuster Potential
- When it comes to possibilities of outsized rewards, few sectors can beat out biotech stocks with blockbuster potential. Fundamentally, the underlying sector enjoys a massive footprint.
- 05/24/2023
|
Travere Therapeutics, Inc. (TVTX) Q1 2023 Earnings Call Transcript
- Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Naomi Eichenbaum - VP, IR Eric Dube - President, CEO and Director Jula Inrig - Chief Medical Officer Christopher Cline - CFO Peter Heerma - Chief Commercial Officer William Rote - SVP, Research and Development Conference Call Participants Maury Raycroft - Jefferies Greg Harrison - Bank of America Joseph Schwartz - SVB Securities Leon Wang - Barclays Liisa Bayko - Evercore ISI Laura Chico - Wedbush Securities Vamil Divan - Guggenheim Securities Alex Thompson - Stifel Ed Arce - HC Wainwright Operator Good day, and welcome to the Travere Therapeutics First Quarter 2023 Financial Results and Corporate Update Conference Call. Today's conference is being recorded.
- 05/07/2023
|
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
- Travere Therapeutics (TVTX) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.20 per share a year ago.
- 05/04/2023
|
Travere Therapeutics stock slides 35% after announcing disappointing results from 2-year trial of kidney drug
- Travere Therapeutics Inc.'s stock TVTX tumbled 35% Tuesday, after the company said data from a two-year study of a kidney drug failed to show a statistically significant improvement. The company said the Phase 3 trial of Sparsentan as a treatment for focal segmental glomerulosclerosis, or FSGS, did not meet the primary efficacy eGFR slope endpoint over 108 weeks of treatment.
- 05/02/2023
|
Travere Therapeutics to Report First Quarter 2023 Financial Results
- SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
- 04/26/2023
|
Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race
- Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race.
- 04/24/2023
|
The Filspari Paradox: Travere's Promising Drug Faces Early-Stage Challenges
- The Filspari Paradox: Travere's Promising Drug Faces Early-Stage Challenges.
- 04/20/2023
|
Chinook: CHK-336 Trial Pause Creates Buying Opportunity, All Eyes On IgAN Readout
- Chinook: CHK-336 Trial Pause Creates Buying Opportunity, All Eyes On IgAN Readout.
- 04/20/2023
|
Travere Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences:
- 03/28/2023
|
3 Up-and-Coming Growth Stocks to Buy Right Now
- Axsome already has two approved drugs and could add two more in the near future. Sarepta has significant growth opportunities with its rare-disease drugs.
- 03/25/2023
|
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
- SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present a quantitative systems pharmacology (QSP) model for predicting the effects of the investigational enzyme replacement therapy pegtibatinase, in classical homocystinuria (HCU), as well as real-world evidence on the prevalence and potential underdiagnosis and/or underreporting of HCU in the United States, at the 2023 Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting in Salt Lake City, UT, March 18-21, 2023. The Company and its collaborators will also provide presentations from the Company's ongoing longitudinal natural history study of people living with HCU, and HCU incidence estimates based on gnomAD database evaluation at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Salt Lake City, UT, March 14-18, 2023.
- 03/14/2023
|
Could an FDA Approval Send This Stock Flying?
- Is now the time to load up on this struggling stock?
- 03/01/2023
|
Travere Therapeutics, Inc. (TVTX) Q4 2022 Earnings Call Transcript
- Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Naomi Eichenbaum - VP, IR Eric Dube - President, CEO & Director Jula Inrig - Chief Medical Officer Christopher Cline - CFO Peter Heerma - Chief Commercial Officer William Rote - SVP, Research & Development Conference Call Participants Gregory Harrison - Bank of America Merrill Lynch Maurice Raycroft - Jefferies Joseph Schwartz - SVB Securities Lachlan Hanbury-Brown - William Blair & Company Antonio Arce - H.C. Wainwright & Co. Carter Gould - Barclays Bank Liisa Bayko - Evercore ISI Alexander Thompson - Stifel, Nicolaus & Company Guyn Kim - Piper Sandler & Co. Laura Chico - Wedbush Securities Operator Good day, and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update.
- 02/23/2023
|
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates
- Travere (TVTX) delivered earnings and revenue surprises of 0.96% and 1.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/23/2023
|
Why Travere Therapeutics Stock Bolted Higher This Week
- A high-value regulatory approval lit a fire underneath the biotech's shares this week.
- 02/23/2023
|
Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
- SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after the close of the U.S. financial markets. Management will provide an update on the financial results and provide a business update in a webcast on February 23, 2023, at 4:30 p.m. ET.
- 02/16/2023
|
Travere: Multiple Catalysts Stacking
- There are other powerful catalysts brewing in the pipeline that would deliver leaping sales growth in the coming years. Sparsentan's Prescription Drug User Fee Act for IgAN is now rescheduled for February 17.
- 02/14/2023
|
Travere: Sparsentan Approval Is Likely, But Future Is Uncertain
- IgA Nephropathy (IgAN) is a chronic autoimmune disease that affects the kidneys and leads to end-stage kidney disease. Current treatments for IgAN are limited in their effectiveness. Sparsentan, developed by Travere Therapeutics, is an experimental drug that targets both the endothelin and angiotensin pathways involved in IgAN.
- 02/13/2023
|
Travere Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences:
- 02/08/2023
|
Travere Therapeutics: Upcoming 'PDUFA' Date For Kidney Disease Therapy Is Critical
- Travere Therapeutics, Inc. is set to find out on Feb 17th whether the FDA has granted accelerated approval to lead drug candidate Sparsentan. Indicated for kidney disease IgAN and FSGS, the accelerated approval would be granted based on the drug's ability to reduce proteinuria.
- 01/26/2023
|
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference, on Thursday, January 12, 2023, at 11:15 a.m. PT.
- 01/03/2023
|
Travere Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences:
- 11/09/2022
|
Travere Therapeutics, Inc. (TVTX) Q3 2022 Earnings Call Transcript
- Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q3 2022 Earnings Conference Call October 27, 2022 4:30 PM ET Company Participants Naomi Eichenbaum - Vice President, Investor Relations Eric Dube - President and Chief Executive Officer Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer William Rote - Senior Vice President of Research and Development Conference Call Participants Maurice Raycroft - Jefferies Greg Harrison - Bank of America Tim Lugo - William Blair Liisa Bayko - Evercore ISI Laura Chico - Wedbush Securities Ed Arce - H.C. Wainwright & Co. Operator Good day and welcome to the Travere Therapeutics Third Quarter 2022 Financial Results and Corporate Update Conference Call.
- 10/27/2022
|
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
- Travere (TVTX) delivered earnings and revenue surprises of -12.37% and 4.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 10/27/2022
|
Travere Therapeutics to Report Third Quarter 2022 Financial Results
- SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2022 financial results on Thursday, October 27, 2022, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
- 10/20/2022
|
Here's Why Travere (TVTX) is Poised for a Turnaround After Losing 22.2% in 4 Weeks
- Travere (TVTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 10/17/2022
|
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
- SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of cognitive function from the Company's ongoing longitudinal natural history study of people living with classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism Annual Symposium in Freiburg, Germany, August 30 – September 2, 2022. Data exploring genomic population-based estimates of the incidence of HCU will also be presented. The Company is currently advancing a novel investigational enzyme replacement therapy, pegtibatinase, for the treatment of HCU.
- 08/25/2022
|
Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q2 2022 Results - Earnings Call Transcript
- Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q2 2021 Earnings Conference Call Aug 0, 2022 8:08 AM ET Company Participants Chris Cline - Senior Vice President, Investor Relations Eric Dube - President and Chief Executive Officer Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Laura Clague - Chief Financial Officer William Rote - Senior Vice President of Research and Development Conference Call Participants Tim Lugo - William Blair Maurice Raycroft - Jefferies Joseph Schwartz - SVB Securities Carter Gould - Barclays Laura Chico - Wedbush Edward Nash - Canaccord Operator Good day and welcome to the Travere Therapeutics Second Quarter Financial Results and Corporate Update. Today's conference is being recorded.
- 08/07/2022
|
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
- Travere (TVTX) delivered earnings and revenue surprises of -11.70% and 9.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
Travere Therapeutics to Report Second Quarter 2022 Financial Results
- SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 8:00 a.m. ET.
- 07/28/2022
|
Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference
- SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET.
- 06/02/2022
|
Here's Why Travere Therapeutics Shares Are Rising Today
- Travere Therapeutics Inc (NASDAQ: TVTX) shares are trading higher by 7.66% at $23.88 after the company received a priority review from the FDA for its treatment of IgA Nephropathy. Travere Therapeutics says the FDA has indicated that it is not currently planning to hold an advisory committee.
- 05/16/2022
|
Travere Therapeutics' (TVTX) CEO Eric Dube on Q1 2022 Results - Earnings Call Transcript
- Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Chris Cline – Senior Vice President-Investor Relations Eric Dube – Chief Executive Officer Jula Inrig – Chief Medical Officer Peter Heerma – Chief Commercial Officer Laura Clague – Chief Financial Officer Bill Rote – Senior Vice President-Research & Development Conference Call Participants Carter Gould – Barclays Mary Kate Davis – Bank of America Liisa Bayko – Evercore ISI Maury Raycroft – Jefferies Tim Lugo – William Blair Laura Chico – Wedbush Securities Ed Arce – H.C. Wainwright and Company Operator Good day, and welcome to the Travere Therapeutics Conference Call.
- 05/08/2022
|
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
- Travere (TVTX) delivered earnings and revenue surprises of -41.18% and 8.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022
- SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU), at the Society for Inherited Metabolic Disorders (SIMD) 43rd Annual Meeting, and the 2022 Genetic Metabolic Dieticians International (GMDI) Conference. In December 2021, the Company announced positive topline results from the COMPOSE Study. The Company and its collaborators will also present real-world evidence from metabolic centers of excellence on current challenges in the dietary management of classical HCU.
- 04/06/2022
|
Travere Therapeutics to Present at the Barclays Global Healthcare Conference
- SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2022 at 8:30 a.m. ET.
- 03/03/2022
|
Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q4 2021 Results - Earnings Call Transcript
- Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q4 2021 Results - Earnings Call Transcript
- 02/24/2022
|
Travere Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results
- SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
- 02/10/2022
|
Travere Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
- SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 2:20 p.m. ET.
- 02/09/2022
|
Travere Therapeutics: Tarpeyo's Approval Is Good News
- Travere Therapeutics: Tarpeyo's Approval Is Good News
- 01/31/2022
|
Travere Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that management will present a Company overview at the following upcoming virtual investor conferences in November:
- 11/11/2021
|
Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021
- SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present abstracts based on non-clinical data describing the potential for sparsentan, an investigational product candidate, to protect kidney function in models of rare glomerular diseases, including a potential anti-inflammatory role in IgA nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2021. Sparsentan is a Dual Endothelin Angiotensin Receptor Antagonist (DEARA) currently in Phase 3 clinical development for the treatment of IgAN and focal segmental glomerulosclerosis (FSGS). The company will also present data from natural history studies highlighting the challenges associated with managing IgAN and FSGS, as well as data indicating poor renal survival in children and adults living with these rare kidney disorders. In addition, an analysis of the association between achieving complete or partial remission of proteinuria and delaying the progression to end-stage kidney disease (ESKD) in FSGS will be presented. ASN Kidney Week 2021 is being held virtually November 4-7, 2021.
- 11/02/2021
|
Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q3 2021 Results - Earnings Call Transcript
- Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q3 2021 Results - Earnings Call Transcript
- 10/28/2021
|
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
- Travere (TVTX) delivered earnings and revenue surprises of 18.06% and 32.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 10/28/2021
|
Travere Therapeutics to Report Third Quarter 2021 Financial Results
- SAN DIEGO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2021 financial results on Thursday, October 28, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
- 10/14/2021
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 74,900 shares of its common stock to eleven new employees, consisting of inducement stock options to purchase an aggregate of 62,100 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 12,800 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
- 10/13/2021
|
Travere Therapeutics Announces Transition of Chief Medical Officer
- SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief medical officer, Noah Rosenberg, M.D., has chosen to transition for personal reasons to an executive advisor role at the end of 2021. Dr. Rosenberg is expected to serve as an advisor to the Company throughout 2022 to assist with clinical trial oversight and regulatory submissions. A search to identify a successor to Dr. Rosenberg is underway while the Company continues to execute its clinical programs as planned.
- 10/12/2021
|
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
- ST. GALLEN, Switzerland & SAN DIEGO, Calif.--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand. Sparsentan is a novel investigational product candidate currently being evaluated in pivotal phase-III clinical studies for the treatment of
- 09/16/2021
|
Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand
- Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand
- 09/15/2021
|
Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors
- Ms. Williams-Brinkley brings more than 35 years of executive leadership experience in healthcare to the Travere Board Ms. Williams-Brinkley brings more than 35 years of executive leadership experience in healthcare to the Travere Board
- 09/14/2021
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,100 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 40,500 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 7,600 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
- 09/13/2021
|
See Why Travere Therapeutics Stock Moving Higher On Tuesday
- Travere Therapeutics Inc (NASDAQ: TVTX) has concluded a Type A meeting with the FDA related to sparsentan in focal segmental glomerulosclerosis (FSGS). See: Travere Therapeutics' Sparsentan Program Submission Pushed to 2022; FDA Requires More Data.
- 09/07/2021
|
Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success
- Shares of Travere Therapeutics remain well below this year's highs despite PROTECT study success. The regulatory update on the FSGS indication of sparsentan has weighed on the share price along with the poor biotech sentiment.
- 08/30/2021
|
Travere (TVTX) Announces Data on Rare Kidney Disease Drug
- Travere (TVTX) announces positive interim data from the ongoing study of its investigational candidate, sparsentan, for the treatment of IgAN, a rare kidney disorder. Resultantly, the stock rises
- 08/17/2021
|
Here's Why Travere Therapeutics Stock Is Climbing Today
- Investors are cheering positive phase 3 trial results with sparsentan that suggest it could become an important new treatment for a rare kidney disease.
- 08/16/2021
|
TVTX Stock: Why Travere Therapeutics Stock Is Rocketing Higher Today
- Travere Therapeutics (TVTX) stock is on the rise Monda and it's all thanks to positive interim results from one of its clinical trials. The post TVTX Stock: Why Travere Therapeutics Stock Is Rocketing Higher Today appeared first on InvestorPlace.
- 08/16/2021
|
Travere Therapeutics Shares Increase Over 30% Pre-Market: Why It Happened
- The shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) increased by over 30% pre-market. This is why it happened.
- 08/16/2021
|
Travere Therapeutics, Inc. (TVTX) CEO Dr. Eric Dube on Q2 2021 Results - Earnings Call Transcript
- Travere Therapeutics, Inc. (TVTX) CEO Dr. Eric Dube on Q2 2021 Results - Earnings Call Transcript
- 07/31/2021
|
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
- Travere (TVTX) delivered earnings and revenue surprises of 12.33% and 8.80%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 07/29/2021
|
Travere Therapeutics to Report Second Quarter 2021 Financial Results
- SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
- 07/22/2021
|
Travere: Setback Presents Cautious Opportunity
- Travere suffered two major setbacks recently. The stock is trading at 52-week lows as a result.
- 07/18/2021
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 89,950 shares of its common stock to eleven new employees, consisting of inducement stock options to purchase an aggregate of 65,100 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 24,850 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
- 07/14/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Travere and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 06/05/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Robert S.
- 06/01/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
- New York, New York--(Newsfile Corp. - May 29, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Travere and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 05/29/2021
|
Travere Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in June:
- 05/27/2021
|
Why Travere Therapeutics Stock Is Plummeting Today
- The FDA quashes the company's hopes for accelerated approval of a key pipeline drug.
- 05/26/2021
|
Travere Therapeutics' Sparsentan Program Submission Pushed to 2022; FDA Requires More Data
- Following the pre-NDA meeting, the FDA has asked Travere Therapeutics Inc (NASDAQ: TVTX) to submit additional data for the sparsentan program in focal segmental glomerulosclerosis (FSGS), characterized by scarring (sclerosis) in the kidney. The agency indicated that the available data from the interim assessment of the DUPLEX Phase 3 study would not be adequate to support an accelerated approval at this time.
- 05/26/2021
|
Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis
- Conference call and webcast to be held at 4:30p.m. ET Conference call and webcast to be held at 4:30p.m. ET
- 05/25/2021
|
Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q1 2021 Results - Earnings Call Transcript
- Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q1 2021 Results - Earnings Call Transcript
- 05/09/2021
|
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
- Travere (TVTX) delivered earnings and revenue surprises of -71.43% and -5.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/06/2021
|
Travere Therapeutics to Report First Quarter 2021 Financial Results
- SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
- 04/26/2021
|
Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q4 2020 Results - Earnings Call Transcript
- Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q4 2020 Results - Earnings Call Transcript
- 03/01/2021
|
Travere Therapeutics (TVTX) Reports Q4 Loss, Lags Revenue Estimates
- Travere (TVTX) delivered earnings and revenue surprises of -451.16% and -0.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2021
|
Travere Therapeutics: Q4 Earnings Insights
- Shares of Travere Therapeutics (NASDAQ:TVTX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 31.43% over the past year to ($0.48), which missed the estimate of ($0.47).
- 03/01/2021
|
Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
- Recently reported that ongoing DUPLEX Study of sparsentan in FSGS achieved interim proteinuria endpoint
- 03/01/2021
|
A Preview Of Travere Therapeutics's Earnings
- Travere Therapeutics (NASDAQ:TVTX) unveils its next round of earnings this Monday, March 01. Get prepared with Benzinga's ultimate preview for Travere Therapeutics's Q4 earnings.
- 02/26/2021
|
Travere Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in February and March:
- 02/22/2021
|
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/22/2021
|
Why Earnings Season Could Be Great for Travere Therapeutics (TVTX)
- Travere Therapeutics (TVTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/19/2021
|
Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy
- SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the European Commission (EC) has granted orphan designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD). Sparsentan is an investigational product candidate currently being evaluated in a pivotal Phase 3 clinical study for the treatment of IgAN, as well as a pivotal Phase 3 clinical study for the treatment of focal segmental glomerulosclerosis (FSGS). The Company recently reported that the ongoing DUPLEX Study of sparsentan in FSGS achieved its pre-specified interim proteinuria endpoint and that preliminary results from the interim analysis suggest that to date in the study, sparsentan has been generally well-tolerated and has shown a comparable safety profile to irbesartan. Topline data from the interim proteinuria assessment in the ongoing PROTECT Study of sparsentan in IgAN remain on track to be reported in the third quarter of 2021.
- 02/18/2021
|
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
- SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 7,532,500 shares of its common stock at a price to the public of $26.75 per share, including 982,500 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Travere. Including the option exercise, the aggregate gross proceeds from the offering were approximately $201.5 million, before deducting the underwriting discounts and commissions and offering expenses.
- 02/17/2021
|
Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results
- SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2020 financial results on Monday, March 1, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
- 02/16/2021
|
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
- SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 6,550,000 shares of its common stock at a price to the public of $26.75 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be approximately $175.2 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on February 17, 2021, subject to customary closing conditions. In addition, Travere has granted the underwriters for the offering a 30-day option to purchase up to an additional 982,500 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
- 02/11/2021
|
Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
- Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment
- 02/02/2021
|
Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy
- SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD). Sparsentan is an investigational product candidate currently being evaluated for the treatment of IgAN, as well as focal segmental glomerulosclerosis (FSGS) in pivotal Phase 3 clinical trials that are expected to report topline data from interim proteinuria assessments in 2021.
- 01/12/2021
|
Travere Therapeutics Provides Corporate Update and 2021 Outlook
- Pipeline of potential first-in-class therapies on track to deliver two pivotal readouts in 2021 Pipeline of potential first-in-class therapies on track to deliver two pivotal readouts in 2021
- 01/11/2021
|
